On Monday, Dean Foods Co (NYSE:DF)’s shares declined -0.06% to $17.80.
Dean Foods Company (DF) will host a live webcast of its second quarter 2015 earnings conference call on August 10 at 9:00 a.m. Eastern Time. Administration will talk about the financial results, in addition to comment on the forward outlook.
Dean Foods Company, a food and beverage company, processes and distributes milk, and other dairy and dairy case products in the United States. It manufactures, markets, and distributes dairy case products, counting fluid milk, ice cream, cultured dairy products, creamers, ice cream mix, and other dairy products; and produces and distributes juices, teas, and bottled water.
CytRx Corporation (NASDAQ:CYTR)’s shares dropped -0.74% to $2.70.
CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, recently stated financial results for the three months ended June 30, 2015, and also offered an overview of recent accomplishments and forthcoming milestones for its clinical development programs.
Second Quarter 2015 and Recent Highlights
Strengthened the Corporate Balance Sheet. In July 2015, CytRx successfully accomplished a public offering of common stock securing gross proceeds of about $28.8 million. CytRx intends to use the net proceeds of the offering to fund clinical trials of its drug candidate aldoxorubicin and its drug discovery activities and for general corporate purposes, which will comprise pre-commercialization activities regardingaldoxorubicin, working capital and capital expenditures.
CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate is aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi’s sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with soft tissue sarcoma; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors.
At the end of Monday s trade, Novo Nordisk A/S (ADR) (NYSE:NVO)‘s shares surged 2.15% to $60.23.
Mr. Jakob Riis, Executive Vice President, China, Pacific & Marketing, Novo Nordisk A/S, is happy to declare the appointment of Mr. Brian Hilberdink to the role of President, Novo Nordisk Canada Inc.
Mr. Hilberdink is an accomplished executive with 20 years of global and domestic experience developing and executing Novo Nordisk’s commercial strategy. He formerly held the position of Vice President, Diabetes Marketing and Market Access, Novo Nordisk Canada. Preceding to this role, Brian was Corporate Vice President, Global Marketing, Novo Nordisk A/S, and led the commercialization of the company’s future insulin portfolio, from phase 2 clinical development until the first launches in Europe and Japan. He also has experience working in the U.S. where, as Director, Brand Administration, he led multiple brand teams during a period of noteworthy growth for Novo Nordisk U.S.
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, in addition to other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. T
MedAssets, Inc. (NASDAQ:MDAS), ended its Monday’s trading session with 1.29% gain, and closed at $23.60.
MedAssets, Inc. (MDAS) declared results for its second quarter and six-month period ended June 30, 2015,
Total net revenue for the second quarter of 2015 raised 8.6% to $190.4 million from $175.4 million for the second quarter of 2014. Not taking into account the revenue contribution from Sg2 (attained on September 22, 2014), total net revenue growth was 1.8% on a year-over-year basis.
Net revenue in the SCM segment raised 13.2% to $119.9 million from $105.9 million for the second quarter of 2014 due to the contribution from Sg2 and growth in advisory solutions consulting fees, partially offset by a slight decline in group purchasing net administrative fees. Not taking into account Sg2, second quarter SCM net revenue raised 2.0% on a year-over-year basis. Net revenue in the RCM segment raised 1.4% to $70.5 million from $69.5 million for the second quarter of 2014 as technology-related revenue (67.4% of RCM segment revenue) was flat while services-related revenue raised 4.4%.
MedAssets, Inc., a performance improvement company, provides technology-enabled products and services for hospitals, health systems, non-acute healthcare providers, payers, and other service providers and product manufacturers in the United States. It operates in two segments, Spend and Clinical Resource Administration (SCM) and Revenue Cycle Administration (RCM). The SCM segment provides a suite of cost administration services, supply chain analytics, and data capabilities; planned sourcing and group purchasing services; and medical device and clinical resource consulting, lean performance improvement, workforce administration, and supply chain outsourcing and procurement services. This segment also provides business intelligence and decision support tools.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
